New blood test could predict heart transplant complications before they happen

NCT ID NCT06939751

Recruiting now Knowledge-focused Sponsor: Northwestern University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This study is looking for tiny molecules in the blood called microRNAs that can help doctors tell if a heart transplant patient's immune system is too active (causing rejection) or too weak (causing infection). Researchers will follow 250 adult heart transplant recipients for one year, collecting blood samples and tracking health outcomes. The goal is to create a simple blood test that helps doctors adjust anti-rejection medicines more precisely, reducing dangerous side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIAC FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure transplant rejection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIAC FAILURE GRAFT REJECTION

Contacts and locations

Locations

Baylor University Medical Center
RECRUITING

Dallas, Texas, 75246, United States
Cedars-Sinai Medical Center
RECRUITING

Los Angeles, California, 90048, United States
Medical University of South Carolina
RECRUITING

Charleston, South Carolina, 29425, United States
Stanford University
RECRUITING

Palo Alto, California, 94304, United States
Tufts Medical Center
RECRUITING

Boston, Massachusetts, 02111, United States
Vanderbilt University
RECRUITING

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.